{"id":42330,"date":"2023-05-10T14:31:43","date_gmt":"2023-05-10T18:31:43","guid":{"rendered":"https:\/\/medcitynews.com\/?p=634191"},"modified":"2024-04-02T22:19:20","modified_gmt":"2024-04-03T02:19:20","slug":"rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/","title":{"rendered":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-424368\" src=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300-600x356.jpg\" alt=\"Red seal and imprint &quot;FDA APPROVED&quot; on white surface. FDA - Food and Drug Administration is a federal agency of the United States Department of Health and Human Services.\" width=\"600\" height=\"356\" srcset=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300-600x356.jpg 600w, https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300-300x178.jpg 300w, https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg 767w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/p>\n<p>A drug developed by partners Protalix BioTherapeutics and Chiesi Group has won <a href=\"https:\/\/www.prnewswire.com\/news-releases\/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-fda-approval-of-elfabrio-pegunigalsidase-alfa-iwxj-for-the-treatment-of-fabry-disease-301820680.html\" target=\"_blank\" rel=\"noopener\">FDA approval<\/a>, a regulatory decision that follows the product\u2019s <a href=\"https:\/\/www.prnewswire.com\/news-releases\/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-authorization-of-prx-102-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease-301817012.html\" target=\"_blank\" rel=\"noopener\">European approval<\/a> last week, introducing new competition for the treatment of a rare disorder with few therapeutic options.<\/p>\n<p>The FDA approval covers the treatment of adults who have Fabry disease, a rare inherited enzyme deficiency. The drug, known in development as pegunigalsidase alfa, will be commercialized in the U.S. under the brand name Elfabrio.<\/p>\n<p>In <a href=\"https:\/\/rarediseases.org\/rare-diseases\/fabry-disease\/\" target=\"_blank\" rel=\"noopener\">Fabry disease<\/a>, a genetic mutation leads to insufficient levels of alpha galactosidase, an enzyme needed to break down a fatty substance called globotriaosylceramide (Gb3). The enzyme deficiency leads to the accumulation of Gb3 in tissues throughout the body, leading to pain, organ damage, and organ failure.<\/p>\n<p>Standard treatment for Fabry disease is enzyme replacement therapy. Sanofi\u2019s Fabrazyme, an engineered version of alpha galactosidase, has been available in Europe since 2001 and in the U.S. since 2003. Replagal, marketed by Takeda Pharmaceutical, has been available in Europe since 2001. It is not approved in the U.S. Both Fabrazyme and Replagal are administered as infusions every other week.<\/p>\n<p>The <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-rare-genetic-disorder-fabry-disease\" target=\"_blank\" rel=\"noopener\">2018 FDA approval of Galafold<\/a> from Amicus Therapeutics introduced another therapeutic option for Fabry. Rather than replacing the deficient enzyme, Galafold is designed to increase the activity of the alpha galactosidase that a patient already has. The capsule, taken once every other day, is intended for Fabry patients with a certain genetic mutation.<\/p>\n<p>Elfabrio is an engineered version of alpha galactosidase administered as an infusion every two weeks. This enzyme replacement therapy is designed to offer a long half-life, but the clinical data so far have not established that Elfabrio\u2019s half-life gives it a safety or efficacy edge. Protalix and Chiesi initially sought accelerated FDA approval for Elfabrio in 2020. In 2021, the agency rejected the drug, citing the need to inspect the drug\u2019s manufacturing facility. No safety or efficacy issues were raised, but travel restrictions in 2021 due to the Covid-19 pandemic hindered the FDA\u2019s ability to inspect the manufacturing sites of Elfabrio and many other drugs.<\/p>\n<p>The timing of the rejection letter threw another obstacle in Elfabrio\u2019s path. The FDA noted that the accelerated approval of Sanofi\u2019s Fabrazyme had recently been converted to full regulatory approval. That meant that any resubmission of an application for Elfabrio would need to address the Sanofi product.<\/p>\n<p>The resubmission of Elfabrio last fall was based on clinical data from more than 140 patients, both those who have previously received enzyme replacement therapy and those who have not. The application included results from a head-to-head study against Fabrazyme showing Elfabrio met the main goal of demonstrating that it was comparable to the Sanofi product in controlling decline as measured by estimated glomerular filtration rate, an assessment of kidney function.<\/p>\n<p>The most common adverse effects reported in Elfabrio\u2019s clinical trials included infusion-associated reactions, cold symptoms, headache, diarrhea, fatigue, and nausea. The drug\u2019s label carries a black box warning that flags the risk of hypersensitivity reactions including anaphylaxis. Clinical trial results showed that 20 (14%) of Elfabrio-treated patients experienced anaphylaxis.<\/p>\n<p>\u201cWhile much progress has been made in the treatment of Fabry disease, there is still a need for new treatment options,&#8221; Giacomo Chiesi, head of Chiesi Global Rare Diseases, said in a prepared statement. \u201cWe established Chiesi Global Rare Diseases to deliver innovative therapies and solutions for people affected by rare diseases. With the FDA approval of Elfabrio, we can now offer people living with Fabry disease an alternative treatment option.&#8221;<\/p>\n<p>Chiesi and Protalix have not said when they plan to launch Elfabrio, nor have they disclosed a price for the drug. They will be going up against Fabry therapies well established in the market. Sanofi\u2019s Fabrazyme generated \u20ac938 million in sales in 2022, an 11% increase over prior year sales. But its patents have expired and biosimilar versions pose competition in some parts of the world. For the fiscal year ended March 31, 2022, Takeda reported 51.7 billion Japanese yen (about $384.6 million) in revenue from Replagal. That figure was flat compared to the prior fiscal year. Amicus reported $329 million in Galafold sales for 2022.<\/p>\n<p><em>Photo: Waldemarus, Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.<\/p>\n","protected":false},"author":25932,"featured_media":28275,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,63,123,54,24],"tags":[48835,12102,48836,41479,6207,14895,19695],"class_list":["post-42330","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-daily","category-legal","category-pharma-channel","category-top-story","tag-chiesi-group","tag-clinical-trials","tag-elfabrio","tag-fabry-disease","tag-fda","tag-protalix-biotherapeutics","tag-rare-disease"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News\" \/>\n<meta property=\"og:description\" content=\"A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-10T18:31:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-03T02:19:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"767\" \/>\n\t<meta property=\"og:image:height\" content=\"455\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda\",\"datePublished\":\"2023-05-10T18:31:43+00:00\",\"dateModified\":\"2024-04-03T02:19:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg\",\"keywords\":[\"Chiesi Group\",\"Clinical Trials\",\"Elfabrio\",\"Fabry disease\",\"FDA\",\"Protalix Biotherapeutics\",\"rare disease\"],\"articleSection\":[\"BioPharma\",\"Daily\",\"Legal\",\"Pharma\",\"Top Story\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\",\"url\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\",\"name\":\"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg\",\"datePublished\":\"2023-05-10T18:31:43+00:00\",\"dateModified\":\"2024-04-03T02:19:20+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg\",\"width\":767,\"height\":455},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/","og_locale":"en_US","og_type":"article","og_title":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News","og_description":"A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.","og_url":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/","og_site_name":"MedCity News","article_published_time":"2023-05-10T18:31:43+00:00","article_modified_time":"2024-04-03T02:19:20+00:00","og_image":[{"width":767,"height":455,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda","datePublished":"2023-05-10T18:31:43+00:00","dateModified":"2024-04-03T02:19:20+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/"},"wordCount":695,"image":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg","keywords":["Chiesi Group","Clinical Trials","Elfabrio","Fabry disease","FDA","Protalix Biotherapeutics","rare disease"],"articleSection":["BioPharma","Daily","Legal","Pharma","Top Story"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/","url":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/","name":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg","datePublished":"2023-05-10T18:31:43+00:00","dateModified":"2024-04-03T02:19:20+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2017\/05\/GettyImages-670645300.jpg","width":767,"height":455},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2023\/05\/rare-disease-drug-fda-approval-enzyme-replacement-therapy-sanofi-takeda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/42330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=42330"}],"version-history":[{"count":0,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/42330\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/28275"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=42330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=42330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=42330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}